Cargando…

Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment

BACKGROUND: Hypoxia is inherent character of most solid malignancies, leading to the failure of chemotherapy, radiotherapy and immunotherapy. Atovaquone, an anti-malaria drug, can alleviate tumor hypoxia by inhibiting mitochondrial complex III activity. The present study exploits atovaquone/albumin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Simeng, Zhou, Xinrui, Zeng, Zekun, Sui, Mengjun, Chen, Lihong, Feng, Chao, Huang, Chen, Yang, Qi, Ji, Meiju, Hou, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487475/ https://www.ncbi.nlm.nih.gov/pubmed/34600560 http://dx.doi.org/10.1186/s12951-021-01034-9

Ejemplares similares

The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
por: Ashton, Thomas M., et al.
Publicado: (2016)

TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer
por: Wang, Zhixiong, et al.
Publicado: (2023)

Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment
por: Zheng, Jun, et al.
Publicado: (2023)

Antimalarial pharmacology and therapeutics of atovaquone
por: Nixon, Gemma L., et al.
Publicado: (2013)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Atovaquone/proguanil‐induced autoimmune‐like hepatitis
por: Terziroli Beretta‐Piccoli, Benedetta, et al.
Publicado: (2017)

Reversible Cerebral Vasoconstriction Syndrome due to Atovaquone
por: Makino, Takahiro, et al.
Publicado: (2017)

Defeating Melanoma Through a Nano-Enabled Revision of Hypoxic and Immunosuppressive Tumor Microenvironment
por: Yang, Wenzhe, et al.
Publicado: (2023)

Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
por: Li, Sen, et al.
Publicado: (2021)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

The hypoxic tumour microenvironment
por: Petrova, Varvara, et al.
Publicado: (2018)

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
por: Lin, Weimin, et al.
Publicado: (2018)

Plasmodium falciparum Malaria and Atovaquone-Proguanil Treatment Failure
por: Durand, Rémy, et al.
Publicado: (2008)

Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
por: Bakshi, Rahul P., et al.
Publicado: (2018)

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
por: Blanshard, Andrew, et al.
Publicado: (2021)

Atovaquone: An Inhibitor of Oxidative Phosphorylation as Studied in Gynecologic Cancers
por: Kapur, Arvinder, et al.
Publicado: (2022)

Tolerability of Atovaquone—Proguanil Application in Common Buzzard Nestlings
por: Wiegmann, Anja, et al.
Publicado: (2022)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade
por: Li, Qiuyi, et al.
Publicado: (2022)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)

PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours
por: Davern, Maria, et al.
Publicado: (2022)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Atovaquone ameliorate gastrointestinal Toxoplasmosis complications in a pregnancy model
por: Oz, Helieh S., et al.
Publicado: (2012)

A survey on outcomes of accidental atovaquone–proguanil exposure in pregnancy
por: Tan, Kathrine R., et al.
Publicado: (2018)

1895. The Anti-Parasitic Drug Atovaquone Inhibits Arbovirus Replication
por: Kottkamp, Angelica, et al.
Publicado: (2018)

Efficacy of Azithromycin and Compounded Atovaquone for Treatment of Babesia gibsoni in Dogs
por: Kirk, S.K., et al.
Publicado: (2017)

Exosomal protein angiopoietin-like 4 mediated radioresistance of lung cancer by inhibiting ferroptosis under hypoxic microenvironment
por: Zhang, Yuhong, et al.
Publicado: (2022)

Light-triggered photosynthetic engineered bacteria for enhanced-photodynamic therapy by relieving tumor hypoxic microenvironment
por: Yin, Chenyang, et al.
Publicado: (2023)

Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
por: Wang, Shuhang, et al.
Publicado: (2022)

Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy
por: Wakiyama, Hiroaki, et al.
Publicado: (2022)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

Targeting hypoxic tumor microenvironment in pancreatic cancer
por: Tao, Jinxin, et al.
Publicado: (2021)

TiSe(2)-mediated sonodynamic and checkpoint blockade combined immunotherapy in hypoxic pancreatic cancer
por: Chen, Libin, et al.
Publicado: (2022)

Toxoplasmosis complications and novel therapeutic synergism combination of diclazuril plus atovaquone
por: Oz, Helieh S.
Publicado: (2014)

The epidemiological survey for atovaquone resistant related gene of Babesia gibsoni in Japan
por: IGUCHI, Aiko, et al.
Publicado: (2015)

Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone
por: Skinner-Adams, Tina S., et al.
Publicado: (2019)

1024. Evaluation of Atovaquone Prescribing for Pneumocystis jiroveci Pneumonia (PJP) Prophylaxis
por: Aleissa, Muneerah, et al.
Publicado: (2019)

Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria‐Targeted Atovaquone
por: Huang, Mofei, et al.
Publicado: (2022)

525. Atovaquone for Treatment of COVID-19 (Ataq COVID-19) Trial
por: Jain, Mamta K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_60fk8eql8fd5ugh32l3g67q5qh